161 related articles for article (PubMed ID: 22453099)
41. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
[TBL] [Abstract][Full Text] [Related]
42. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.
Davis TA; Maloney DG; Grillo-López AJ; White CA; Williams ME; Weiner GJ; Dowden S; Levy R
Clin Cancer Res; 2000 Jul; 6(7):2644-52. PubMed ID: 10914705
[TBL] [Abstract][Full Text] [Related]
43. Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias.
Gupta P; Goldenberg DM; Rossi EA; Chang CH
Blood; 2010 Oct; 116(17):3258-67. PubMed ID: 20628151
[TBL] [Abstract][Full Text] [Related]
44. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
Maloney DG; Grillo-López AJ; Bodkin DJ; White CA; Liles TM; Royston I; Varns C; Rosenberg J; Levy R
J Clin Oncol; 1997 Oct; 15(10):3266-74. PubMed ID: 9336364
[TBL] [Abstract][Full Text] [Related]
45. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
46. Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study.
Kinoshita T; Hatake K; Yamamoto K; Higuchi Y; Murakami S; Terui Y; Yokoyama M; Maruyama D; Makita S; Hida Y; Saito T; Tobinai K
Jpn J Clin Oncol; 2021 Jan; 51(1):70-77. PubMed ID: 33029633
[TBL] [Abstract][Full Text] [Related]
47. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.
Antonarakis ES; Carducci MA; Eisenberger MA; Denmeade SR; Slovin SF; Jelaca-Maxwell K; Vincent ME; Scher HI; Morris MJ
Cancer Chemother Pharmacol; 2012 Mar; 69(3):763-71. PubMed ID: 22020316
[TBL] [Abstract][Full Text] [Related]
48. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
Witzig TE; Tomblyn MB; Misleh JG; Kio EA; Sharkey RM; Wegener WA; Goldenberg DM
Haematologica; 2014 Nov; 99(11):1738-45. PubMed ID: 25150258
[TBL] [Abstract][Full Text] [Related]
49. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
[TBL] [Abstract][Full Text] [Related]
50. Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.
Cheah CY; Belada D; Fanale MA; Janikova A; Czucman MS; Flinn IW; Kapp AV; Ashkenazi A; Kelley S; Bray GL; Holden S; Seymour JF
Lancet Haematol; 2015 Apr; 2(4):e166-74. PubMed ID: 26687959
[TBL] [Abstract][Full Text] [Related]
51. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
Morschhauser F; Kraeber-Bodéré F; Wegener WA; Harousseau JL; Petillon MO; Huglo D; Trümper LH; Meller J; Pfreundschuh M; Kirsch CM; Naumann R; Kropp J; Horne H; Teoh N; Le Gouill S; Bodet-Milin C; Chatal JF; Goldenberg DM
J Clin Oncol; 2010 Aug; 28(23):3709-16. PubMed ID: 20625137
[TBL] [Abstract][Full Text] [Related]
52. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
53. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.
Sausville EA; Headlee D; Stetler-Stevenson M; Jaffe ES; Solomon D; Figg WD; Herdt J; Kopp WC; Rager H; Steinberg SM
Blood; 1995 Jun; 85(12):3457-65. PubMed ID: 7780133
[TBL] [Abstract][Full Text] [Related]
54. SM03, an Anti-CD22 Antibody, Converts
Wong KL; Li Z; Ma F; Wang D; Song N; Chong CH; Luk KK; Leung SO
J Immunol; 2022 Jun; 208(12):2726-2737. PubMed ID: 35688465
[TBL] [Abstract][Full Text] [Related]
55. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
[TBL] [Abstract][Full Text] [Related]
56. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
57. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
[TBL] [Abstract][Full Text] [Related]
58. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
59. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
[TBL] [Abstract][Full Text] [Related]
60. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F
Blood; 1998 Sep; 92(6):1927-32. PubMed ID: 9731049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
